“This course contains the use of artificial intelligence.”

The pharmaceutical industry is currently navigating a fundamental transition in its research and development paradigm. Entering 2024–2025, the shift from empirical, trial-and-error methodologies to predictive, AI-driven frameworks has become a strategic necessity for global biopharma enterprises. This course provides a comprehensive examination of how generative AI—specifically Large Language Models (LLMs) and diffusion models—is being integrated into the R&D lifecycle to compress discovery timelines and improve the probability of clinical success.

The curriculum begins with an analysis of the evolution of R&D timelines, contrasting legacy systems with modern computational design. Participants will explore the core mechanisms of biological generative models, understanding how these architectures treat molecular sequences as semantic data and spatial geometries. This foundational knowledge is then applied to target identification and validation, where generative frameworks are used to synthesize multi-omics data and map complex disease mechanisms with high precision.

Moving into the lead discovery phase, the course details the application of Generative Adversarial Networks (GANs) and transformers for de novo molecular design. Learners will evaluate how AI-enhanced virtual screening and automated docking protocols allow for the evaluation of ultra-large chemical libraries in a fraction of the time required by traditional physics-based methods. A critical focus is placed on early-stage ADMET property prediction, demonstrating how in silico forecasting can prevent costly late-stage failures.

The scope extends to the clinical stage, covering the generation of synthetic data and digital twins for robust preclinical modeling. Participants will learn how machine learning optimizes clinical trial protocols and patient selection, alongside the use of LLMs to automate regulatory documentation, such as Clinical Study Reports and Investigator Brochures. Finally, the course addresses the vital components of implementation: data governance, intellectual property protection, and the integration of proprietary AI with legacy biological databases.

This course is designed for professionals seeking to lead or support AI transformation within life sciences. It provides the technical depth and strategic oversight required to navigate the complexities of modern drug development. The content is updated to reflect the latest advancements in multimodal AI and the emerging role of quantum integrations in molecular simulation, ensuring learners are equipped with the most current insights for the 2025 landscape.